Trending Stocks: Bed Bath & Beyond (NASDAQ:BBBY), FireEye (NASDAQ:FEYE), BioCryst Pharmaceuticals (NASDAQ:BCRX), Rite Aid (NYSE:RAD)

Posted by on Apr 10, 2014

Bed Bath & Beyond Inc. (NASDAQ:BBBY) stock slid in after-hours TRADING as the company announced results for its fourth quarter and full fiscal 2013 (FY13; ended March 1, 2014). The company also issued full-year guidance, which fell below the Street’s estimates. Bed Bath & Beyond Inc. (NASDAQ:BBBY) shares after opening at $68.03 moved to $68.20 on last trade day and at the end of the day closed at $67.91. Company price to sales ratio in past twelve months was calculated as 1.24 and price to cash ratio as 20.83. Bed Bath & Beyond Inc. (NASDAQ:BBBY) showed a negative weekly performance of -2.19%.

FireEye Inc. (NASDAQ:FEYE) reported fourth quarter revenue of $57.3 million, reflecting 81 percent increase from one year ago quarter. The operating loss in the quarter came in at $61.4 million. FireEye Inc. (NASDAQ:FEYE) shares advanced 7.72% in last trading session and ended the day on $56.39. FEYE return on equity ratio is recorded as -38.90% and its return on assets is -22.80%.

On March 28, 2014, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and the U.S. Department of Health and Human Services (“HHS”) mutually agreed to amend the Agreement dated January 3, 2007 between the Company and HHS (the “Agreement”) to extend the Agreement’s current expiration date of March 31, 2014 for 30 days. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved up 3.38% in last trading session and was closed at $9.78, while trading in range of $9.32 – $9.83. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date (YTD) performance is 28.68%.

Rite Aid Corporation (NYSE:RAD) announced it has acquired Houston-based RediClinic, one of the nation’s leading operators of retail clinics. Rite Aid Corporation (NYSE:RAD) weekly performance is 0.63%. On last trading day company shares ended up $6.40. Rite Aid Corporation (NYSE:RAD) distance from 50-day simple moving average (SMA50) is 1.65%. Analysts mean target price for the company is $6.62.

Leave a Reply

Your email address will not be published. Required fields are marked *